Pictilisib was found to increase the antitumor activity of taxanes, with an associated increase in apoptotic cell death, in multiple breast cancer xenografts [25] and, in combination with trastuzumab, synergistically inhibited cell proliferation and the PI3K signaling pathway in HER2-amplified breast cancer cell lines [26]. This evidence concerns the gene PIK3CD and breast carcinoma.